Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The therapy has shown positive results in Phase III trials in both breast and lung cancer. Due to a delayed US launch it remains a drug to watch for 2024.

Drugs 173

Drugs Therapies Treatment Virus 173

Vial

MARCH 1, 2024

Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market. billion by 2029. By revenue, the largest CRO in the US was Thermo Fisher Scientific Inc.,

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52

Agency IQ

FEBRUARY 2, 2024

BY LAURA DIANGELO, MPH | JAN 30, 2024 10:25 AM CST Diagnostic regulation: A quick overview Diagnostics products are those intended to identify, signal or detect a specific health condition, infection or disease, or monitor a person’s health or health status. The diagnostics landscape in the U.S.:

FDA 40

FDA Regulations Laboratories Production 40

Drug Discovery World

JULY 26, 2024

The strategy is aimed at keeping the sector competitive in a country that has recently been struggling to maintain relevance in the global medical device and clinical trials scenes. With an anticipated annual growth rate of 7.61%, they are predicted to reach US$12.57bn by 2029.

Science 130

Science Government Biosimilars Marketing 130